Sun Pharma’s phase 3 clinical studies evaluating ILUMYA in active psoriatic arthritis met their primary endpoint Read more
Lilly’s orforglipron and other key catalysts can reshape drug landscape in Q3 2025: GlobalData Read more
Aim to gain market share, preserve cash, reduce overall debt in times of COVID-19: Dilip Shanghvi Read more
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA for Middle East & North Africa regions Read more
Sun Pharma presents insights into clinical use of ILUMYA in moderate-to-severe plaque psoriasis Read more